Eli Lilly and Company (LILY34) — Cash Flow Reinvestment Rate
Eli Lilly and Company (LILY34) has a Cash Flow Reinvestment Rate of 0.92x as of December 2025, reinvesting R$2.98 Billion (capex R$2.97 Billion plus investments R$5.00 Million) from operating cash flow of R$3.22 Billion. Explore Eli Lilly and Company capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Eli Lilly and Company Cash Flow Reinvestment Rate (2014–2025)
Historical reinvestment intensity for Eli Lilly and Company across 12 annual periods. Also explore LILY34 total asset value for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Eli Lilly and Company (2014–2025)
Year-by-year capital reinvestment analysis for Eli Lilly and Company. For live market cap and broader valuation context, see LILY34 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (BRL) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.66x | R$11.17 Billion | R$16.81 Billion | R$10.85 Billion | ▼ -66.9% |
| 2024 | 2.01x | R$17.71 Billion | R$8.82 Billion | R$8.40 Billion | ▲ +8.7% |
| 2023 | 1.85x | R$10.55 Billion | R$5.71 Billion | R$5.88 Billion | ▲ +523.4% |
| 2022 | 0.30x | R$2.10 Billion | R$7.08 Billion | R$1.85 Billion | ▲ +45.7% |
| 2021 | 0.20x | R$1.48 Billion | R$7.26 Billion | R$1.31 Billion | ▼ -48.1% |
| 2020 | 0.39x | R$2.55 Billion | R$6.50 Billion | R$2.03 Billion | ▲ +4.7% |
| 2019 | 0.37x | R$1.81 Billion | R$4.84 Billion | R$1.35 Billion | ▼ -74.6% |
| 2018 | 1.47x | R$8.13 Billion | R$5.52 Billion | R$3.02 Billion | ▲ +203.1% |
| 2017 | 0.49x | R$2.73 Billion | R$5.62 Billion | R$2.16 Billion | ▼ -44.3% |
| 2016 | 0.87x | R$4.23 Billion | R$4.85 Billion | R$1.09 Billion | ▲ +16.1% |
| 2015 | 0.75x | R$2.23 Billion | R$2.96 Billion | R$1.07 Billion | ▼ -30.0% |
| 2014 | 1.07x | R$4.79 Billion | R$4.46 Billion | R$1.16 Billion | — |